ASCO is urging lawmakers to ensure America continues to lead in research through continued bipartisan support for federal health agencies and the scientists driving daily progress. Ahead of the April ...

SPARGO, Inc. is the only official registration and housing provider for ASCO Meetings and Symposia. Individuals unaffiliated with ASCO or SPARGO, Inc. may entice prospective attendees into registering ...

CMS proposes a 2.4% increase in operating payment rates for general acute care hospitals paid under IPPS that successfully participate in the Hospital Inpatient Quality Reporting (IQR) program and are ...

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur: On April 23, 2025, the Food and Drug Administration approved penpulimab-kcqx (Akeso Biopharma ...

The 2025 ASCO Annual Meeting is The Place to Be—a global gathering where oncology professionals connect, collaborate, and inspire. Known for advancing the field, this must-attend event offers an ...

Members of the Association for Clinical Oncology (ASCO) were on Capitol Hill on April 8, 2025, for the 10th annual ASCO Advocacy Summit, where they met with lawmakers to discuss critical issues in ...

For reference, please review the following policies and guidelines. As you prepare your submission to the Meeting, please make note of the following author and sponsorship eligibility criteria: ...

The U.S. Supreme Court issued an opinion on Wednesday, April 2, that the Food and Drug Administration (FDA) was within its power to regulate the sale of certain flavored e-cigarette products. The case ...

Several presidential appointees have been confirmed to lead key health agencies that the Association for Clinical Oncology (ASCO) will work with during the new administration. These include: Robert F.

The deadline for early registration and hotel reservations is April 23, 2025, at 11:59 PM ET. Below you will find registration rates and details, hotel information, and links to book your hotel and ...

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur: On April 11, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers ...

A U.S. District Court has vacated the April 2024 Food and Drug Administration’s (FDA) final rule that would have regulated laboratory-developed tests (LDTs) as medical devices. The rule was set to ...